Levodopa-induced dyskinesias are improved by fluoxetine

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms.
• Dyskinesias are common motor complications of PD treatment, often induced by dopamine agonists like apomorphine.
• Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has been investigated for its potential effects on PD symptoms.

Purpose of the Study:

• To evaluate the effect of fluoxetine on apomorphine-induced dyskinesias in Parkinson's disease patients.
• To assess whether fluoxetine modifies parkinsonian motor disability.
• To explore the role of serotoninergic pathways in dopamine agonist-induced dyskinesias.

Main Methods:

• Seven levodopa-responsive PD patients underwent an acute apomorphine challenge.
• Dyskinesias and motor disability were assessed before and after an 11-day course of fluoxetine (20 mg twice daily).
• Statistical analysis was performed to determine the significance of observed changes.

Main Results:

• Fluoxetine treatment resulted in a significant 47% improvement in apomorphine-induced dyskinesias (p < 0.05).
• No significant modification of parkinsonian motor disability was observed.
• Dyskinesia reduction was noted in specific limbs and at different times relative to apomorphine dosing.

Conclusions:

• Increased brain serotoninergic transmission via fluoxetine may reduce dopamine agonist-induced dyskinesias in Parkinson's disease.
• Fluoxetine appears to improve dyskinesias without worsening motor symptoms of Parkinson's disease.
• These findings suggest a potential therapeutic role for SSRIs in managing PD treatment complications.